Receiving inappropriate or unnecessary antibiotics for asymptomatic bacteriuria or urinary tract infections can lead to unnecessary side effects. In this multicenter, pre- and post-test study, we evaluate the effect of an antimicrobial stewardship initiative focusing on appropriate diagnosis and treatment of cystitis and pyelonephritis in patients seen at inpatient institutions in the emergency room. The primary endpoint is fluoroquinolone and oral third generation cephalosporin antibiotics use for lower urinary tract infections (UTIs) (per total antibiotics prescribed for lower UTIs). Secondary endpoints include appropriateness of empiric antibiotics for the treatment of pyelonephritis and cystitis and cases of asymptomatic bacteriuria treated with antibiotics per total cases of suspected UTIs.
A clinical study for people with recurrent Clostridium difficile infection (CDI), which is an infection in the intestines. This infection causes severe diarrhea. Recurrent Clostridium difficile (C. diff) infection is being studied as part of a medical research study for an investigational new drug called RBX2660, an enema made of a solution of stool (poop or feces).
The regular use of ertapenem in hemodialysis (HD) patients warrants further exploration of optimal dosing of the drug, especially those which may minimize toxicity and improve adherence. This is a prospective study designed to characterize the drug concentration profile of an alternate dosing regimen (ertapenem 1 gram given three times weekly) in non-infected HD patients. The ultimate aim is to determine if ertapenem given three times weekly achieves adequate dosing targets to treat established infections and identify an optimal dosing scheme for ertapenem among patients on HD.
When a chest tube is placed, it can be hard for the fluid to drain. Tissue plasminogen activator and DNase are given through the chest tube to help with draining the fluid. We are doing this research to see if early addition of tPA-DNase will help with better fluid draining.
This study is for patients who have received a kidney, liver, or pancreas transplant and who have developed resistant Cytomegalovirus infection. There will be two treatment groups to compare the improvement or resolution of Cytomegalovirus infection. Subjects will be randomized to receive 8 weeks of either the investigational drug, Maribavir, or physician assigned standard of care treatment.
Non-cystic fibrosis (CF) bronchiectasis is a lung disease characterized by dilation of the airways. Patients often suffer from chronic airways infection. One such associated infection is non-tuberculosis mycobacterium (NTM) lung disease, which is 50 to 75 times more common in patients with bronchiectasis than those without it. The decision to initiate treatment (for NTM pulmonary disease) is not straightforward, hinging on how the patient feels and excluding other causes for their symptoms. Symptoms patients frequently report are pulmonary related (e.g. cough, sputum production, and coughing up blood) and constitutional symptoms (e.g. fevers, weight loss and body aches). When treatment is started for NTM lung disease, it can be for many months to years and has many potential side effects. The scientific literature rarely reports outcomes of treatment from a patient's perspective, which could aid a physician's decision to initiate treatment and/or response to treatment of the patient's NTM disease. This study will 1) create a Patient Registry for patients with bronchiectasis and/or NTM disease with an emphasis on patient reported outcomes (PRO) using questionnaires and 2) prospectively collect and analyze the clinical data for patients seen in the MUSC Bronchiectasis and/or NTM clinic
This is a study comparing two methods of dressing a post operative wound that are currently in practice. One method is a traditional dry gauze dressing. The other method is using a negative pressure dressing that provides gentle suction on the wound.
We will attempt to determine how well the use of post-operative negative pressure dressing reduces wound healing problems in patients who have surgery after radiation for a sarcoma in the thigh or leg.
Treatment of chronic hepatitis C virus (HCV) infection is now possible with all oral medications. While most patients achieve a sustained virologic response (SVR) after treatment, synonymous with cure, some patients relapse after treatment for reasons that are unclear. The goal of this research is to understand how a person's immune system changes during treatment of HCV infection with all oral therapy, and how these changes might impact the chances of relapse after treatment. To address these questions, blood and clinical information will be collected from study participants over the course of receiving standard of care treatment for HCV infection. This blood and clinical information will be used to conduct laboratory research focused on the immune system.
Pitavastatin lowers high cholesterol and triglyceride levels in the blood. The primary purpose of this study is to determine the effects of pitavastatin on lowering the traditional risk factors for cardiological events in patients who have HIV.